Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspectiveStephen Chaplin, Edward Li, Anna Chen et al.|Journal of Managed Care & Specialty Pharmacy|2024Cited by 5
A budget impact model for biosimilar denosumab for skeletal-related events and fractures in the United States oncology populationJeanine Flanigan, G.H. Lyman, Stephen Chaplin et al.|Journal of Medical Economics|2025Cited by 1